28 patents
Utility
Cytotoxic and anti-mitotic compounds, and methods of using the same
4 Apr 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. Winters, Alexander Laurence Mandel, James R. Rich, Bradley John Hedberg, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, John Babcook
Filed: 11 Feb 19
Utility
Cytotoxic and anti-mitotic compounds, and methods of using the same
28 Feb 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. Winters, James R. Rich, Graham Albert Edwin Garnett, Alexander Laurence Mandel, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, Stuart Daniel Barnscher
Filed: 26 Jul 19
Utility
Anti-PD-L1-anti-TIM-3 bispecific antibodies
7 Jun 22
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Yi Zhang, Igor Edmondo Paolo D'Angelo
Filed: 12 Mar 19
Utility
Bispecific antigen-binding constructs targeting Her2
10 May 22
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 18 Jun 18
Utility
Modified antigen binding polypeptide constructs and uses thereof
19 Apr 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
Filed: 29 May 15
Utility
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
29 Mar 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 5 Sep 18
Utility
Multivalent heteromultimer scaffold design and constructs
15 Feb 22
Provided herein are multifunctional heteromultimer proteins.
Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
Filed: 21 May 19
Utility
Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
28 Dec 21
The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues.
John Babcook, James R. Rich, Jan Peter Bergqvist, Stuart Daniel Barnscher
Filed: 23 Dec 14
Utility
Checkpoint inhibitor bispecific antibodies
21 Dec 21
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman
Filed: 9 Jul 18
Utility
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
2 Nov 21
Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain.
Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
Filed: 7 Oct 16
Utility
Drug-conjugated bi-specific antigen-binding constructs
19 Oct 21
Bispecific antigen-binding constructs e.g., antibodies conjugated to drugs (ADCs), which bind CD3 and other cell-surface target antigen such as tumor antigens e.g., CD19, CDH3, HER2, HER3 and EGFR antigens and methods of use are disclosed.
Gordon Yiu Kon Ng, Leonard G. Presta, Thomas Spreter Von Kreudenstein
Filed: 15 Jul 16
Utility
Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
19 Oct 21
The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule.
Paula I. Lario, Johannes Mullegger, Surjit B. Dixit, Tomas Rodinger, Powell Patrick Cheng Tan
Filed: 27 Jul 16
Utility
Heteromultimers with reduced or silenced effector function
24 Aug 21
Provided herein are heteromultimer constructs with reduced or silenced effector function.
Eric Escobar-Cabrera
Filed: 30 May 14
Utility
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
3 Aug 21
Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain.
Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 14 Feb 18
Utility
Anti-PD-1/LAG3 bispecific antibodies
27 Jul 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
Filed: 31 Jan 19
Utility
Antigen-binding constructs targeting HER2
8 Jun 21
Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2.
Eric Escobar-Cabrera, Leonard G. Presta
Filed: 13 May 16
Utility
Systems and methods for identifying thermodynamically relevant polymer conformations
8 Jun 21
Systems, methods and non-transitory computer readable media identify favored polymer conformations.
Gregory Lakatos, Surjit Bhimarao Dixit
Filed: 21 Jun 13
Utility
Anti-HER2 biparatopic antibody-drug conjugates and methods of use
11 May 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K. C. Fung, Stuart D. Barnscher
Filed: 7 Oct 19
Utility
Bispecific antigen-binding constructs targeting HER2
16 Mar 21
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 27 Nov 14
Utility
Stable heterodimeric antibody design with mutations in the Fc domain
28 Dec 20
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g.
Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
Filed: 17 Jan 17